News
Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre, discusses the trial design of a study comparing amivantamab with standard chemotherapy to potentially improve treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback